Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

PharmARC - ASCO 2011 Twitter Analysis of Top Links Shared and Comments on Molecules (3rd through 7th june)


Published on

PharmARC analysed the post conference social media buzz on Twitter for the American Society of Clinical Oncology (ASCO) 2011 conference held in Chicago

  • The Internet is the last great frontier before space, the deep sea, and Middle Earth. Questions abound as to how this massive inter-networking of computer networks does what it does and doesn't do what it's supposed to. These questions, and answers thereto, may be found within this forum.
    Are you sure you want to  Yes  No
    Your message goes here

PharmARC - ASCO 2011 Twitter Analysis of Top Links Shared and Comments on Molecules (3rd through 7th june)

  1. 1. ASCO 2011 Twitter Analytics June 3 – 7, 2011, Chicago, Illinois Prepared by: PharmARC Analytic Solutions Rohit Kumar [email_address] +91 97314 58005
  2. 2. Contents <ul><li>Top Links and Abstracts Shared at ASCO (3 rd – 7 th June) </li></ul><ul><li>Tweets on Molecules at ASCO (29 th May – 7 th June) </li></ul>
  3. 3. Top Links and Abstracts Shared (June 3 rd – 7 th )
  4. 4. Top Links Shared (1/4) <ul><li>These are the top stories (URLs/links) shared most in twitter, for the Twitter hashtag ASCO11 (shared as tiny URLs) </li></ul><ul><li>The ones shared below include only the ones that were tweeted/re-tweeted the most from 3 rd June through 7 th June </li></ul>Title URL Salient Points Cancer’s New Era Of Promise And Chaos <ul><li>George Sledge, the outgoing president of the ASCO, talks about the changing paradigm in oncology w.r.t. new technology (genomic chaos, ‘stupid’ vs. ‘smart’ cancers, biomarkers validating the genomics, enormous data generation, health information technology) </li></ul><ul><li>Every oncologist will need to be a clinical cancer biologist </li></ul><ul><li>216 LinkedIn shares; tweeted >50 times </li></ul>NCI at ASCO 2011: Partnering for Progress <ul><li>Mentions the ASCO sessions and activities at National Cancer Institute booth </li></ul><ul><li>Tweeted >45 times </li></ul>Should Twitter be Restricted at Scientific Meetings? <ul><li>Apparently some meetings such as the Biology of Genomes Conference at Cold Spring Harbor Laboratory, presenters have to grant permission to allow the use of Twitter (this apparently will not be the case at ASCO) </li></ul><ul><li>Tweeted >25 times </li></ul>Ovarian Cancer Screening Does Not Appear to Reduce Risk of Ovarian Cancer Death <ul><li>JAMA publication: “We conclude that annual screening for ovarian cancer as performed in the PLCO trial with simultaneous CA-125 and transvaginal ultrasound does not reduce disease-specific mortality in women at average risk for ovarian cancer but does increase invasive medical procedures and associated harms,” the author (Christine D. Berg, M.D.) writes </li></ul><ul><li>Tweeted >20 times </li></ul>Random attacks cause concern in Chicago,0,7509040.story?track=rss&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+chicagotribune%2Fnews%2Flocal+(Chicago+Tribune+news+-+Local+news) <ul><li>&quot;I think it reflects badly on Chicago,&quot; said Dr. Jack Singer, 68, a Seattle oncologist who was one of two victims in town for a convention of cancer specialists at McCormick Place. &quot;I've been coming to the convention every year, and this is the first time I've felt threatened downtown.“ </li></ul><ul><li>Tweeted ~20 times </li></ul>The University of Texas The M.D. Anderson Cancer Center <ul><li>Info about the M.D. Anderson Cancer Center and ASCO </li></ul><ul><li>Tweeted ~20 times </li></ul>
  5. 5. Top Links Shared (2/4) Title URL Salient Points Scientific Meetings through the Lens of Twitter <ul><li>One of the most useful things about Twitter at meetings is the real-time feedback from colleagues who come at the talks from different angles – Dr. David Kroll of North Carolina Central University </li></ul><ul><li>Concerns about the accuracy of tweets may contribute to the reluctance of some presenters to have their work tweeted during meetings, particularly unpublished findings that have not been through peer review </li></ul><ul><li>Tweeted ~20 times </li></ul>Novartis Oncology global site <ul><li>Novartis oncology media page, providing links including news from ASCO </li></ul><ul><li>Tweeted ~15 times </li></ul> Home page <ul><li>Authoritative resource for adult cancer patients and the parents of children with cancer who want to learn more about preserving their fertility before and during cancer treatment, and protecting their hormonal health after treatment </li></ul><ul><li>Tweeted ~15 times </li></ul>Clinical Trials Day at ASCO <ul><li>Monday, June 6, the Clinical Trials Day at the Annual Meeting </li></ul><ul><li>Features sessions that focus on a variety of themes relevant to the progress of clinical trials </li></ul><ul><li>Tweeted ~15 times </li></ul>Amgen medical info page <ul><li>Links for iPhone/iPad, Blackberry and Android (coming soon) for Amgen medical information download </li></ul><ul><li>Tweeted ~15 times </li></ul>Direct-to-Consumer Genetic Testing: Personalized Medicine in Evolution <ul><li>DTC genetic testing has the potential to launch personalized medicine to a height never before anticipated if technologic, social, and ethical issues are effectively addressed </li></ul><ul><li>Tweeted ~15 times </li></ul>ASCO 2011 Annual Meeting schedule <ul><li>Details of the poster sessions (schedule) </li></ul><ul><li>Tweeted >10 times </li></ul>
  6. 6. Top Links Shared (3/4) Title URL Salient Points ASCO Experiment: One-Stop Commenting for Cancer Research <ul><li>Proposes ASCO opening up its abstracts to commenting </li></ul><ul><li>Shares a spreadsheet collating comments from social media on some ASCO abstracts </li></ul><ul><li>Tweeted >10 times </li></ul>New Glioblastoma Cancer Vaccine Shows Promise in Phase 2 Trial <ul><li>&quot;This study confirms our theory that a vaccine is capable of causing a favorable immune response in patients with brain tumors,” said Jeffrey Bruce, MD, Edgar M. Housepian Professor of Neurological Surgery Research at New York-Presbyterian Hospital/Columbia University Medical Center </li></ul><ul><li>Tweeted >10 times </li></ul>Personalized Therapy Benefits Late-Stage Cancer Patients in Clinical Trial <ul><li>&quot;This study affirms what we in the cancer community have been talking about for a decade -- matching drugs to patients,&quot; says Razelle Kurzrock, M.D., chair of the Department of Investigational Therapeutics and director of MD Anderson's Phase I clinical trials program </li></ul><ul><li>Tweeted >10 times </li></ul>“ The Cancer That Gives Cancer a Bad Name”: Important News on the Treatment of Advanced Melanoma <ul><li>Dr. Len’s cancer blog </li></ul><ul><li>“ I don't keep a record of these sorts of things, but I suspect the speed of &quot;start to finish&quot; to prove significant improvement in responses and survival is right up there with the fastest clinical trials on record. The reason for this &quot;record&quot; is pretty clear when you read the report and look at the data: almost every patient who was treated with vemurafenib responded to the drug, and most of them responded very quickly.” </li></ul><ul><li>Tweeted ~10 times </li></ul>Primary Care Doctors and Medical Oncologists Have Different Concerns About Providing Survivorship Care <ul><li>Medical oncologists were more likely to be concerned that patients might get duplicate care and about which doctor should provide general preventive care </li></ul><ul><li>Primary care doctors were more concerned about having appropriate training to provide sufficient follow-up care. They were also more likely than oncologists to recommend additional tests or treatments out of concerns of malpractice </li></ul><ul><li>According to lead author Katherine Virgo, PhD, MBA, Managing Director of Health Services Research at the American Cancer Society in Atlanta, it’s important for patients to talk with both their oncologist and primary care doctor and make sure that information about their treatment and follow-up care recommendations is being shared </li></ul><ul><li>Tweeted ~10 times </li></ul>
  7. 7. Top Links Shared (4/4) Title URL Salient Points Melanoma: Ready for Takeoff <ul><li>“ It’s possible that you can combine targeted agents along the same circuit, like a BRAF drug and an MEK inhibitor,” says Hwu, department chairman of the melanoma medical oncology department at M.D. Anderson Cancer Center in Houston. “Or you can combine two targeted agents on separate circuits.” </li></ul><ul><li>As one example, GlaxoSmithKline has launched a series of studies looking at an MEK inhibitor (GSK1120212) and a BRAF inhibitor (GSK2118436), both separately and in combination </li></ul><ul><li>Tweeted ~10 times </li></ul>The University of Texas MD Anderson Cancer Center Education Page <ul><li>Lists the Residency and Fellowship Programs </li></ul><ul><li>Tweeted ~10 times </li></ul>ASCO '11: Roche, Bristol Melanoma Drugs Shine <ul><li>Bristol's Yervoy was approved earlier this year and Roche's vemurafenib is still under regulatory review, but both drugs could generate $1 billion or more in sales, analysts say </li></ul><ul><li>Tweeted ~10 times </li></ul>The Genomic Era: We Have Reached A New Tipping Point In Cancer Research And Treatment <ul><li>There was one lecture where the researcher showed a large box that looked to be the size of a refrigerator which can analyze the entire genome of a person or a cancer over a matter of days, followed by the prediction (that many share) that these types of tests--which were the stuff of science fiction just a few short years ago--will be routine at a reasonable cost in a very short period of time (in fact, some well-known cancer centers are already employing this technology as part of their routine evaluation of a patient's cancer) </li></ul><ul><li>Tweeted ~10 times </li></ul>ASCO Wrap-Up: The Skinny on Cancer News From All Corners of the U.S. <ul><li>Summary of what the companies presented at ASCO (Ariad Pharmaceuticals, Infinity Pharmaceuticals, Synta Pharmaceuticals, Alnylam Pharmaceuticals, Constellation Pharmaceuticals, Genentech/Plexxikon, Exelixis, ACT Biotech, Onyx Pharmaceuticals, Genomic Health, Dendreon, Seattle Genetics, Pfizer, Merck, VentiRx Pharmaceuticals, Ligand Pharmaceuticals) </li></ul><ul><li>Tweeted ~10 times </li></ul>
  8. 8. Top Abstracts Shared Title URL Salient Points Effect of screening on ovarian cancer mortality in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer randomized screening trial <ul><li>Screening simultaneously with CA-125 and TVU did not reduce ovarian cancer mortality in women from the general population, and there was evidence of harm from diagnostic evaluation following a false positive screening test. </li></ul><ul><li>Tweeted ~20 times </li></ul>Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma <ul><li>IPI (10mg/kg) + DTIC significantly improved OS in 1st line metastatic melanoma vs DTIC alone; durable survival and objective responses were noted in some pts after follow-up for up to 4yrs. Type of AEs was consistent with prior IPI studies; however, frequencies of some AEs differed with a higher transaminitis and lower diarrhea/colitis/ GI perforation rates than expected. No drug-related deaths were noted in IPI arm. OS benefit of IPI is confirmed in treatment-naive metastatic melanoma </li></ul><ul><li>Tweeted ~15 times </li></ul>OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC) <ul><li>Results show a statistically significant and clinically relevant benefit when bevacizumab is added to chemotherapy in patients with recurrent, platinum sensitive EOC, PPC, and FTC. This is the first phase III trial of an antiangiogenic to demonstrate a clinical benefit to these patients </li></ul><ul><li>Tweeted ~15 times </li></ul>Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma <ul><li>Vemurafenib is associated with significantly improved OS and PFS compared to DTIC in pts with previously untreated, V600E BRAF-mutated metastatic melanoma </li></ul><ul><li>Tweeted ~15 times </li></ul>NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer <ul><li>The majority of women with node positive breast cancer are now managed by BCS followed by WBI and adjuvant systemic therapy. Results from MA.20 demonstrate that additional RNI reduces the risk of locoregional and distant recurrence, and improves DFS with a trend in improved OS </li></ul><ul><li>Tweeted >10 times </li></ul>Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial <ul><li>BuMel was demonstrated to be superior to CEM and hence is recommended as standard treatment </li></ul><ul><li>Tweeted >10 times </li></ul>
  9. 9. Tweets on Molecules (29 th May – 7 th June)
  10. 10. More than 15 Peak Tweets bevacizumab: the most buzzed drug at ASCO 2011 vemurafenib-ipilimumab: a new era for the melanoma treatment – BMS & Roche combination therapy
  11. 11. Less than 15 Peak Tweets
  12. 12. vemurafenib (PLX 4032) <ul><ul><li>Ipilimumab & vemurafenib - Melanoma takes center stage </li></ul></ul><ul><ul><ul><li>BRIM-3 editorial: Vemurafenib’s availability a defining moment; will have important effect on survival, QOL </li></ul></ul></ul><ul><ul><ul><li>Lynn Schuchter, Penn: on trial results (vemurafenib, ipilimumab+dacarbazine) - an unprecedented time for celebration for patients </li></ul></ul></ul><ul><ul><ul><li>Melanoma smart pill #vemurafenib starts working in 72 hours, Prof Lynn Schuchter tells </li></ul></ul></ul><ul><ul><ul><li>Maybe I'm in a minority, but ipilimumab data are a tad disappointing - 2 months OS over DTIC. Vemurafenib data more impressive </li></ul></ul></ul><ul><ul><ul><li>BRAF vemurafenib data impressive w/ incr ORR PFS&OS:a1st! duration may be short -resistance is inevitable & opp for new drugs/combos </li></ul></ul></ul><ul><ul><ul><li>personalized med finally becoming a reality,eg $ROG vemurafenib for melanoma; $ECYT EC145 for </li></ul></ul></ul><ul><ul><ul><li>Third post-plenary thought re: #melanom--how long until Vemurafenib no longer monotherapy? Lots of combos in the works #asco11play resistant ovarian cancer </li></ul></ul></ul><ul><ul><ul><li>Melanoma_doctor: Vemurafenib (&quot;V-Fib&quot;) shows 73% reduction in risk of death. Pretty damn significant </li></ul></ul></ul><ul><ul><ul><li>Vemurafenib article #NEJM w/ improved OS + PFS for #melanoma pts, FDA approval inevitable </li></ul></ul></ul><ul><ul><ul><li>Is #Melanoma Rhetoric Outpacing Reality? Vemurafenib & Yervoy Have Limitations Despite Positive Trials. Why? #ASCO11 </li></ul></ul></ul><ul><ul><ul><ul><li> Has the historical dearth of viable pharmacotherapies for malignant melanoma led to an overreaction to the positive phase III Yervoy and vemurafenib data presented at the plenary session? </li></ul></ul></ul></ul><ul><ul><li>Cost concerns </li></ul></ul><ul><ul><ul><li>If the vemurafenib-ipilimumab combo data come in positive, where will the costs go? Through the roof :( #asco11) </li></ul></ul></ul>
  13. 13. Yervoy (ipilimumab) <ul><ul><li>Ipilimumab & vemurafenib - Melanoma takes center stage </li></ul></ul><ul><ul><ul><li>Tweets discuss BMS & Roche combination therapy (vemurafenib-ipilimumab) being in the limelight </li></ul></ul></ul><ul><ul><ul><li>Maybe I'm in a minority, but ipilimumab data are a tad disappointing - 2 months OS over DTIC. Vemurafenib data more impressive #asco11 </li></ul></ul></ul><ul><ul><ul><li>Is #Melanoma Rhetoric Outpacing Reality? Vemurafenib & Yervoy Have Limitations Despite Positive Trials. Why? #ASCO11 </li></ul></ul></ul><ul><ul><ul><ul><li> Has the historical dearth of viable pharmacotherapies for malignant melanoma led to an overreaction to the positive phase III Yervoy and vemurafenib data presented at the plenary session? </li></ul></ul></ul></ul><ul><ul><li>Cost concerns </li></ul></ul><ul><ul><ul><li>If the vemurafenib-ipilimumab combo data come in positive, where will the costs go? Through the roof :( #asco11 </li></ul></ul></ul><ul><ul><ul><li>@teamoncology to put it in context, if you need ipilimumab, your 20% co-pay will be $24K. Yikes. #asco11 </li></ul></ul></ul>
  14. 14. Avastin (bevacizumab) <ul><ul><li>Bevacizumab in ovarian cancer (OCEANS trial) was most tweeted </li></ul></ul><ul><ul><ul><li>#ASCO11 practical considerations. Bevacizumab in ovarian cancer manage HTN aggressively. Waiting for oceans/icon 7 later today </li></ul></ul></ul><ul><ul><ul><li>#ASCO11 Avastin shows trend towards improved OS in ICON7 ovarian cancer trial, greater effect in high risk patients. Good for approval? Nope </li></ul></ul></ul><ul><ul><ul><li>#asco11 Avastin in Ovarian Cancer ~ no big surprise with +ve data! Wonder if FDA will drag feet to approve or will move quickly? LBA5006/7 </li></ul></ul></ul><ul><ul><li>Cost concerns </li></ul></ul><ul><ul><ul><li>45% of Avastin use in United Heath Group centers is used outside NCCN guidelines #ASCO11 HUGE cost </li></ul></ul></ul>
  15. 15. Tarceva (erlotinib) <ul><ul><li>Erlotinib is superior to chemotherapy in EGFR mutated NSCLC patients and expects FDA filing </li></ul></ul><ul><ul><ul><li>Longtime member of @cancerGRACE community wants me to hug makers of Tarceva at #ASCO11 for him, as his wife is doing very well on it </li></ul></ul></ul><ul><ul><ul><li>INNOVATIONS subgrp analysis of EGFR Mut+ interesting -small numbers. Q: Beva interfere with erlotinib delivery/efficacy? #ASCO11 #BOPA </li></ul></ul></ul><ul><ul><ul><li>Erlotinib/bev vs. chemo/bev as 1st line Rx for adv nonsquam NSCLC, no select'n for EGFR mutn: chemo/bev clearly better, dets later #ASCO11 </li></ul></ul></ul><ul><ul><ul><li>EURTAC study: RR diff 58% vs. 14%, along w/huge PFS diff 9.7 vs 3.2 mo favoring erlotinib in EGFR mut NSCLC pts. Expect FDA filing. #ASCO11 </li></ul></ul></ul>
  16. 16. Revlimid (lenalidomide) <ul><ul><li>Lenalidomide for the treatment of Multiple Myeloma and Prostate Cancer proves impressive </li></ul></ul><ul><ul><ul><li>Ravandi now reviewing Revlimid in MDS (Alan list abstract). Also says new agents in dev for AML are promising and worth pursuing #ASCO11 </li></ul></ul></ul><ul><ul><ul><li>#ASCO11 #myeloma Lenalidomide is a fundamental drug in the treatment of Multiple Myeloma </li></ul></ul></ul><ul><ul><ul><li>Avastn/Revlimid/Tax combo data in PCa was early, but impressive. Toxic, but not as bad as I would have guessed 1D/4574 #ASCO11 </li></ul></ul></ul>
  17. 17. Glivec (imatinib) <ul><ul><li>3 years Glivec improves RFS / OS in patients with GIST </li></ul></ul><ul><ul><ul><li>#ASCO11: 3 yrs of imatinib for GIST likely &quot;will be standard,&quot; says Heikki Joensuu, M.D., University of Helsinki. (SSGXVIII/AIO trial) </li></ul></ul></ul><ul><ul><ul><li>#ASCO11: Imatinib results in GIST (SSGXVIII/AIO trial): &quot;This is the kind of data that will change guidelines.&quot; Mark Kris, Sloan-Kettering </li></ul></ul></ul>
  18. 18. Alimta (pemetrexed) <ul><ul><li>Maintenance therapy with Alimta for NSCLC was most tweeted </li></ul></ul><ul><ul><ul><li>Likely to be biggest practice changing abstract for NSCLC at #ASCO11 maintenance pemetrexed vs BSC </li></ul></ul></ul><ul><ul><ul><li>Overall, amrubicin v topotecan trial reminds me of topo v CAV in SCLC, or pemetrexed v docetaxel in NSCLC. I'd welcome amru option </li></ul></ul></ul>
  19. 19. Zytiga (abiraterone) <ul><ul><li>Cost concerns </li></ul></ul><ul><ul><ul><li>Drake: With cost structure of abiraterone, docs will still use ketoconozole #ASCO11 </li></ul></ul></ul><ul><ul><ul><li>@MaverickNY I disagree. Zytiga more expensive for Medicare *patients* than Provenge. #ASCO11 </li></ul></ul></ul><ul><ul><ul><li>William Oh - pca mkt getting crowded (cabazitaxel, abiraterone, sipu, etc) w more in late stage trials (alpharadin, Prostvac, etc) #asco11 </li></ul></ul></ul>
  20. 20. Aromasin (exemestane) <ul><ul><li>Breast cancer </li></ul></ul><ul><ul><ul><li>Exemestane’s data for breast cancer prevention is impressive </li></ul></ul></ul><ul><ul><ul><li>@MaverickNY Exemestane is a possible alternative for Tamoxifen. But long-term data & safety needed. Need FDA approval before use. #ASCO11 </li></ul></ul></ul>
  21. 21. Other molecules <ul><ul><li>Ridaforolimus </li></ul></ul><ul><ul><ul><li>Was discussed mostly as a maintenance therapy </li></ul></ul></ul><ul><ul><li>axitinib (AG013736) </li></ul></ul><ul><ul><ul><li>Outperforms sorafenib in Renal Cell Carcinoma </li></ul></ul></ul><ul><ul><li>Sprycel (dasatinib) </li></ul></ul><ul><ul><ul><li>Shows superior major molecular response over imatinib </li></ul></ul></ul><ul><ul><li>alpharadin (radium-223) </li></ul></ul><ul><ul><ul><li>William Oh - pca mkt getting crowded (cabazitaxel, abiraterone, sipu, etc) w more in late stage trials (alpharadin, Prostvac, etc) #asco11 </li></ul></ul></ul><ul><ul><li>Abraxane (paclitaxel ) </li></ul></ul><ul><ul><ul><li>CELG Sticking With Abraxane (despite bad data at #ASCO11) </li></ul></ul></ul><ul><ul><li>Zaltrap (aflibercept) </li></ul></ul><ul><ul><ul><li>Significantly Improved Survival in Previously Treated Metastatic #ColonCancer </li></ul></ul></ul><ul><ul><li>Ruxolitinib (INCB-018424) </li></ul></ul><ul><ul><ul><li>Decreases the spleen size in myelofibrosis </li></ul></ul></ul>
  22. 22. For further information on the analytics, please contact: Rohit Kumar Product Director [email_address] +91 97314 58005